HCPCS Level II code A9590 denotes a 1 millicurie unit of iodine I-131 labeled iobenguane, a radiopharmaceutical used in nuclear medicine for targeted diagnostic imaging and select therapeutic applications. Nationally, accurate coding for radiopharmaceuticals like A9590 affects billing, inventory tracking, and clinical workflow for facilities that administer radioactive agents.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns, reimbursement benchmarks where available, and clinical context for use of iobenguane I-131. Readers will find a concise overview of typical sites of service, relevant service line considerations, common billing modifiers (listed separately), and guidance on documentation elements that support medical necessity determinations.

Coverage and reimbursement practices for radiopharmaceuticals vary by payer and setting; this resource summarizes common contractual approaches and highlights areas where policy updates or local payer edits frequently occur. The piece also provides practical benchmarks for claim line reporting and notes when additional documentation or prior authorization is commonly required. Data not available in the input is identified where applicable.